ALLEGAN, Mich., July 11 /PRNewswire-FirstCall/ -- Perrigo Company
(Nasdaq: PRGO; TASE) today announced that its Board of Directors has
appointed Ellen R. Hoffing as a new director of the Company.
Joseph C. Papa, Perrigo's Chairman, President and Chief Executive
Officer, stated, "Ellen Hoffing's outstanding background has served her
well in leadership roles at several pharmaceutical and healthcare
companies. Her broad business and strategic acumen will allow her to make
excellent contributions to our Board. We are pleased to welcome Ellen to
the Perrigo Board of Directors."
Since 2006, Ellen R. Hoffing, 51, has served as President and Chief
Executive Officer of Applied NeuroSolutions, Inc., a development stage
biopharmaceutical company focused on diagnostics and therapeutics for the
treatment of Alzheimer's Disease. She has also served as Chairman of
Applied NeuroSolutions' Board of Directors since December 2007. Ms. Hoffing
has extensive experience in the pharmaceutical industry, including
management, strategic planning and operations, given her prior senior
positions at American Pharmaceutical Partners (2005-2006), Baxter
Healthcare (2002-2005), and Searle Pharmaceuticals (1983-2000). Ms. Hoffing
has a bachelor of science in accountancy from the University of Illinois at
Urbana -- Champaign and a masters in management from the Kellogg Graduate
School of Management at Northwestern University.
Perrigo Company is a leading global healthcare supplier that develops,
manufactures and distributes over-the-counter (OTC) and prescription
pharmaceuticals, nutritional products, active pharmaceutical ingredients
(API) and consumer products. The Company is the world's largest
manufacturer of OTC pharmaceutical products for the store brand market. The
Company's primary markets and locations of manufacturing facilities are the
United States, Israel, Mexico and the United Kingdom. Visit Perrigo on the
Internet ( http://www.perrigo.com ).
Note: Certain statements in this press release are forward-looking
statements within the meaning of Section 21E of the Securities Exchange Act
of 1934, as amended, and are subject to the safe harbor created thereby.
These statements relate to future events or the Company's future financial
performance and involve known and unknown risks, uncertainties and other
factors that may cause the actual results, levels of activity, performance
or achievements of the Company or its industry to be materially different
from those expressed or implied by any forward-looking statements. In some
cases, forward-looking statements can be identified by terminology such as
"may," "will," "could," "would," "should," "expect," "plan," "anticipate,"
"intend," "believe," "estimate," "predict," "potential" or other comparable
terminology. The Company has based these forward-looking statements on its
current expectations, assumptions, estimates and projections. While the
Company believes these expectations, assumptions, estimates and projections
are reasonable, such forward-looking statements are only predictions and
involve known and unknown risks and uncertainties, many of which are beyond
the Company's control. These and other important factors, including those
discussed under "Risk Factors" in the Company's Form 10-K for the year
ended June 30, 2007, as well as the Company's subsequent filings with the
Securities and Exchange Commission, may cause actual results, performance
or achievements to differ materially from those expressed or implied by
these forward-looking statements. The forward-looking statements in this
press release are made only as of the date hereof, and unless otherwise
required by applicable securities laws, the Company disclaims any intention
or obligation to update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise.
SOURCE Perrigo Company
 back to top
Related links:
http://www.perrigo.com
CONTACT:
Arthur J. Shannon, Vice President, Investor
Relations and Communication, Perrigo Company, +1-269-686-1709,
ajshannon@perrigo.com
|
